Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02542605 · ClinicalTrials.gov registry record · Phase 1
To Evaluate the Blockade of CGRP in Preventing PACAP-38 Induced Migraine-like Attacks With AMG 334 in Migraine Patients
A Phase 1 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
NCT02542605 is a Phase 1 study that has completed, run by Amgen. The registered enrollment target is 35 participants.
The verdict
NCT02542605, a Phase 1 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
Study Summary
Phase I, Randomized, Parallel-group, Double-Blind, Placebo-Controlled, Single Dose Study to Evaluate the Blockade of CGRP Receptor by AMG 334 in Preventing PACAP-38 Induced Migraine-like Attacks in Migraine Patients.
Interventions
- DRUG Placebo
- DRUG Erenumab
- DRUG PACAP-38 Challenge Agent
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2015-11-11 |
| Est. Completion | 2017-11-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02542605
The ClinicalTrials.gov registry entry for NCT02542605 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02542605 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02542605 about?
NCT02542605 is a clinical study titled "To Evaluate the Blockade of CGRP in Preventing PACAP-38 Induced Migraine-like Attacks With AMG 334 in Migraine Patients". Phase I, Randomized, Parallel-group, Double-Blind, Placebo-Controlled, Single Dose Study to Evaluate the Blockade of CGRP Receptor by AMG 334 in Preventing PACAP-38 Induced Migraine-like Attacks in Migraine Patients.
What is the current status of trial NCT02542605?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2015-11-11. Estimated completion is 2017-11-08.
What interventions are being tested in trial NCT02542605?
The interventions under investigation include: Placebo (DRUG), Erenumab (DRUG), PACAP-38 Challenge Agent (DRUG).
Who is sponsoring clinical trial NCT02542605?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.